IWINF - Irwin Naturals' Bold Leap: Cannabis Psychedelics Drive Q3 Buzz Despite Falling Revenue & Surging Losses | Benzinga
Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X), a nutraceutical company leveraging its brand into the cannabis and psychedelics sectors, reported its financial results for the third quarter of fiscal 2023, revealing revenue of $19.1 million, down from $22.0 million in the same period last year and $22.1 million in the previous quarter.
"During the first three quarters of 2023, we successfully launched our branded licensing initiative in our cannabis sector,” Sean Sand, CFO, stated. "Sales have exceeded our expectations and we look forward to continuing our licensing efforts in the space. We also continued to expand our mental health footprint through the acquisition of an industry-leading marketing and patient acquisition platform, Ketamine ...